International Journal of Cancer Management

Published by: Kowsar

Antisense Non-Coding RNA in the INK4 Locus (ANRIL) in Human Cancers

Mohammad Taheri 1 and Soudeh Ghafouri-Fard 2 , *
Authors Information
1 Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • International Journal of Cancer Management: October 2018, 11 (10); e67864
  • Published Online: October 3, 2018
  • Article Type: Review Article
  • Received: February 24, 2018
  • Revised: May 6, 2018
  • Accepted: May 19, 2018
  • DOI: 10.5812/ijcm.67864

To Cite: Taheri M, Ghafouri-Fard S. Antisense Non-Coding RNA in the INK4 Locus (ANRIL) in Human Cancers, Int J Cancer Manag. 2018 ; 11(10):e67864. doi: 10.5812/ijcm.67864.

Abstract
Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Soudyab M, Iranpour M, Ghafouri-Fard S. The role of long non-coding rnas in breast cancer. Arch Iran Med. 2016;19(7):508-17. [PubMed: 27362246].
  • 2. Dianatpour A, Ghafouri-Fard S. The role of long non coding RNAs in the repair of DNA double strand breaks. Int J Mol Cell Med. 2017;6(1):1-12. [PubMed: 28868264]. [PubMed Central: PMC5568187].
  • 3. Eftekharian MM, Ghafouri-Fard S, Soudyab M, Omrani MD, Rahimi M, Sayad A, et al. Expression analysis of long non-coding RNAs in the blood of multiple sclerosis patients. J Mol Neurosci. 2017;63(3-4):333-41. doi: 10.1007/s12031-017-0982-1. [PubMed: 28967047].
  • 4. Dianatpour A, Ghafouri-Fard S. Long non coding RNA expression intersecting cancer and spermatogenesis: A systematic review. Asian Pac J Cancer Prev. 2017;18(10):2601-10. doi: 10.22034/APJCP.2017.18.10.2601. [PubMed: 29072050]. [PubMed Central: PMC5747377].
  • 5. Faramarzi S, Dianatpour A, Ghafouri-Fard S. Discovering the role of long non-coding RNAs in regulation of steroid receptors signaling in cancer. J Biol Today World. 2017;6(12). doi: 10.15412/j.jbtw.01061202.
  • 6. Taheri M, Omrani MD, Ghafouri-Fard S. Long non-coding RNA expression in bladder cancer. Biophys Rev. 2018;10(4):1205-13. doi: 10.1007/s12551-017-0379-y. [PubMed: 29222807]. [PubMed Central: PMC6082308].
  • 7. Nikpayam E, Soudyab M, Tasharrofi B, Sarrafzadeh S, Iranpour M, Geranpayeh L, et al. Expression analysis of long non-coding ATB and its putative target in breast cancer. Breast Dis. 2017;37(1):11-20. doi: 10.3233/BD-160264. [PubMed: 28598827].
  • 8. Taheri M, Habibi M, Noroozi R, Rakhshan A, Sarrafzadeh S, Sayad A, et al. HOTAIR genetic variants are associated with prostate cancer and benign prostate hyperplasia in an Iranian population. Gene. 2017;613:20-4. doi: 10.1016/j.gene.2017.02.031. [PubMed: 28259691].
  • 9. Nikpayam E, Tasharrofi B, Sarrafzadeh S, Ghafouri-Fard S. The role of long non-coding RNAs in ovarian cancer. Iran Biomed J. 2017;21(1):3-15. doi: 10.6091/.21.1.24. [PubMed: 27664137]. [PubMed Central: PMC5141251].
  • 10. Iranpour M, Soudyab M, Geranpayeh L, Mirfakhraie R, Azargashb E, Movafagh A, et al. Expression analysis of four long noncoding RNAs in breast cancer. Tumour Biol. 2016;37(3):2933-40. doi: 10.1007/s13277-015-4135-2. [PubMed: 26409453].
  • 11. Taheri M, Omrani M, Ghafouri-Fard S. Long non-coding RNAs expression in renal cell carcinoma. J Biol Today World. 2017;6(12). doi: 10.15412/j.jbtw.01061201.
  • 12. Khorshidi HR, Taheri M, Noroozi R, Sarrafzadeh S, Sayad A, Ghafouri-Fard S. ANRIL genetic variants in Iranian breast cancer patients. Cell J. 2017;19(Suppl 1):72-8. doi: 10.22074/cellj.2017.4496. [PubMed: 28580310]. [PubMed Central: PMC5448323].
  • 13. Pasmant E, Sabbagh A, Vidaud M, Bieche I. ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J. 2011;25(2):444-8. doi: 10.1096/fj.10-172452. [PubMed: 20956613].
  • 14. Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. 2010;38(5):662-74. doi: 10.1016/j.molcel.2010.03.021. [PubMed: 20541999]. [PubMed Central: PMC2886305].
  • 15. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene. 2011;30(16):1956-62. doi: 10.1038/onc.2010.568. [PubMed: 21151178]. [PubMed Central: PMC3230933].
  • 16. Meseure D, Vacher S, Alsibai KD, Nicolas A, Chemlali W, Caly M, et al. Expression of ANRIL-polycomb complexes-CDKN2A/B/ARF genes in breast tumors: Identification of a two-gene (EZH2/CBX7) signature with independent prognostic value. Mol Cancer Res. 2016;14(7):623-33. doi: 10.1158/1541-7786.MCR-15-0418. [PubMed: 27102007].
  • 17. Popov N, Gil J. Epigenetic regulation of the INK4b-ARF-INK4a locus: In sickness and in health. Epigenetics. 2010;5(8):685-90. [PubMed: 20716961]. [PubMed Central: PMC3052884].
  • 18. Zhao R, Choi BY, Lee MH, Bode AM, Dong Z. Implications of genetic and epigenetic alterations of CDKN2A (p16(INK4a)) in cancer. EBioMedicine. 2016;8:30-9. doi: 10.1016/j.ebiom.2016.04.017. [PubMed: 27428416]. [PubMed Central: PMC4919535].
  • 19. Bostrom J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, Lichter P, et al. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol. 2001;159(2):661-9. doi: 10.1016/S0002-9440(10)61737-3. [PubMed: 11485924]. [PubMed Central: PMC1850553].
  • 20. Simon M, Koster G, Menon AG, Schramm J. Functional evidence for a role of combined CDKN2A (p16-p14(ARF))/CDKN2B (p15) gene inactivation in malignant gliomas. Acta Neuropathol. 1999;98(5):444-52. [PubMed: 10541865].
  • 21. Rousseau E, Ruchoux MM, Scaravilli F, Chapon F, Vinchon M, De Smet C, et al. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathol Appl Neurobiol. 2003;29(6):574-83. [PubMed: 14636164].
  • 22. Gong WJ, Peng JB, Yin JY, Li XP, Zheng W, Xiao L, et al. Association between well-characterized lung cancer lncRNA polymorphisms and platinum-based chemotherapy toxicity in Chinese patients with lung cancer. Acta Pharmacol Sin. 2017;38(4):581-90. doi: 10.1038/aps.2016.164. [PubMed: 28260796]. [PubMed Central: PMC5386317].
  • 23. Nie FQ, Sun M, Yang JS, Xie M, Xu TP, Xia R, et al. Long noncoding RNA ANRIL promotes non-small cell lung cancer cell proliferation and inhibits apoptosis by silencing KLF2 and P21 expression. Mol Cancer Ther. 2015;14(1):268-77. doi: 10.1158/1535-7163.MCT-14-0492. [PubMed: 25504755].
  • 24. Lu Y, Zhou X, Xu L, Rong C, Shen C, Bian W. Long noncoding RNA ANRIL could be transactivated by c-Myc and promote tumor progression of non-small-cell lung cancer. Onco Targets Ther. 2016;9:3077-84. doi: 10.2147/OTT.S102658. [PubMed: 27307748]. [PubMed Central: PMC4888724].
  • 25. Gong WJ, Yin JY, Li XP, Fang C, Xiao D, Zhang W, et al. Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Tumour Biol. 2016;37(6):8349-58. doi: 10.1007/s13277-015-4497-5. [PubMed: 26729200].
  • 26. Ma J, Li T, Han X, Yuan H. Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2018;144(2):205-14. doi: 10.1007/s00432-017-2543-y. [PubMed: 29127494].
  • 27. Huang MD, Chen WM, Qi FZ, Xia R, Sun M, Xu TP, et al. Erratum to: Long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell proliferation by epigenetic silencing of KLF2. J Hematol Oncol. 2017;10(1):143. doi: 10.1186/s13045-017-0513-0. [PubMed: 28950881]. [PubMed Central: PMC5530579].
  • 28. Zhao B, Lu YL, Yang Y, Hu LB, Bai Y, Li RQ, et al. Overexpression of lncRNA ANRIL promoted the proliferation and migration of prostate cancer cells via regulating let-7a/TGF-beta1/ Smad signaling pathway. Cancer Biomark. 2018;21(3):613-20. doi: 10.3233/CBM-170683. [PubMed: 29278879]. [PubMed Central: PMC5859458].
  • 29. Taheri M, Pouresmaeili F, Omrani MD, Habibi M, Sarrafzadeh S, Noroozi R, et al. Association of ANRIL gene polymorphisms with prostate cancer and benign prostatic hyperplasia in an Iranian population. Biomark Med. 2017;11(5):413-22. doi: 10.2217/bmm-2016-0378. [PubMed: 28621612].
  • 30. Xu ST, Xu JH, Zheng ZR, Zhao QQ, Zeng XS, Cheng SX, et al. Long non-coding RNA ANRIL promotes carcinogenesis via sponging miR-199a in triple-negative breast cancer. Biomed Pharmacother. 2017;96:14-21. doi: 10.1016/j.biopha.2017.09.107. [PubMed: 28961506].
  • 31. Lan WG, Xu DH, Xu C, Ding CL, Ning FL, Zhou YL, et al. Silencing of long non-coding RNA ANRIL inhibits the development of multidrug resistance in gastric cancer cells. Oncol Rep. 2016;36(1):263-70. doi: 10.3892/or.2016.4771. [PubMed: 27121324].
  • 32. Zhang EB, Kong R, Yin DD, You LH, Sun M, Han L, et al. Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget. 2014;5(8):2276-92. doi: 10.18632/oncotarget.1902. [PubMed: 24810364]. [PubMed Central: PMC4039162].
  • 33. Sun Y, Zheng ZP, Li H, Zhang HQ, Ma FQ. ANRIL is associated with the survival rate of patients with colorectal cancer, and affects cell migration and invasion in vitro. Mol Med Rep. 2016;14(2):1714-20. doi: 10.3892/mmr.2016.5409. [PubMed: 27314206].
  • 34. Zhang JJ, Wang DD, Du CX, Wang Y. Long noncoding RNA ANRIL promotes cervical cancer development by acting as a sponge of miR-186. Oncol Res. 2017. doi: 10.3727/096504017X14953948675449. [PubMed: 28550682].
  • 35. Qiu JJ, Wang Y, Liu YL, Zhang Y, Ding JX, Hua KQ. The long non-coding RNA ANRIL promotes proliferation and cell cycle progression and inhibits apoptosis and senescence in epithelial ovarian cancer. Oncotarget. 2016;7(22):32478-92. doi: 10.18632/oncotarget.8744. [PubMed: 27095571]. [PubMed Central: PMC5078027].
  • 36. Chen D, Zhang Z, Mao C, Zhou Y, Yu L, Yin Y, et al. ANRIL inhibits p15(INK4b) through the TGFbeta1 signaling pathway in human esophageal squamous cell carcinoma. Cell Immunol. 2014;289(1-2):91-6. doi: 10.1016/j.cellimm.2014.03.015. [PubMed: 24747824].
  • 37. Hu X, Jiang H, Jiang X. Downregulation of lncRNA ANRIL inhibits proliferation, induces apoptosis, and enhances radiosensitivity in nasopharyngeal carcinoma cells through regulating miR-125a. Cancer Biol Ther. 2017;18(5):331-8. doi: 10.1080/15384047.2017.1310348. [PubMed: 28402230]. [PubMed Central: PMC5499759].
  • 38. Wang Y, Cheng N, Luo J. Downregulation of lncRNA ANRIL represses tumorigenicity and enhances cisplatin-induced cytotoxicity via regulating microRNA let-7a in nasopharyngeal carcinoma. J Biochem Mol Toxicol. 2017;31(7). doi: 10.1002/jbt.21904. [PubMed: 28117929].
  • 39. Iacobucci I, Sazzini M, Garagnani P, Ferrari A, Boattini A, Lonetti A, et al. A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia. Leuk Res. 2011;35(8):1052-9. doi: 10.1016/j.leukres.2011.02.020. [PubMed: 21414664].
  • 40. Poi MJ, Li J, Sborov DW, VanGundy Z, Cho YK, Lamprecht M, et al. Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. Mol Carcinog. 2017;56(7):1722-32. doi: 10.1002/mc.22626. [PubMed: 28150872].
  • 41. Royds JA, Pilbrow AP, Ahn A, Morrin HR, Frampton C, Russell IA, et al. The rs11515 polymorphism is more frequent and associated with aggressive breast tumors with increased ANRIL and decreased p16 (INK4a) expression. Front Oncol. 2015;5:306. doi: 10.3389/fonc.2015.00306. [PubMed: 26835415]. [PubMed Central: PMC4720739].
  • 42. Huang MD, Chen WM, Qi FZ, Xia R, Sun M, Xu TP, et al. Long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell apoptosis by epigenetic silencing of KLF2. J Hematol Oncol. 2015;8:50. doi: 10.1186/s13045-015-0146-0. [PubMed: 25966845]. [PubMed Central: PMC4434820].
  • 43. Naemura M, Murasaki C, Inoue Y, Okamoto H, Kotake Y. Long noncoding RNA ANRIL regulates proliferation of non-small cell lung cancer and cervical cancer cells. Anticancer Res. 2015;35(10):5377-82. [PubMed: 26408699].
  • 44. Lin L, Gu ZT, Chen WH, Cao KJ. Increased expression of the long non-coding RNA ANRIL promotes lung cancer cell metastasis and correlates with poor prognosis. Diagn Pathol. 2015;10:14. doi: 10.1186/s13000-015-0247-7. [PubMed: 25889788]. [PubMed Central: PMC4599723].
  • 45. Zhang D, Ding L, Li Y, Ren J, Shi G, Wang Y, et al. Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of lncRNA ANRIL in tumour cells. Sci Rep. 2017;7(1):16231. doi: 10.1038/s41598-017-13431-y. [PubMed: 29176691]. [PubMed Central: PMC5701200].
  • 46. Kang YH, Kim D, Jin EJ. Down-regulation of phospholipase d stimulates death of lung cancer cells involving up-regulation of the long ncRNA ANRIL. Anticancer Res. 2015;35(5):2795-803. [PubMed: 25964559].
  • 47. Zhang D, Sun G, Zhang H, Tian J, Li Y. Long non-coding RNA ANRIL indicates a poor prognosis of cervical cancer and promotes carcinogenesis via PI3K/Akt pathways. Biomed Pharmacother. 2017;85:511-6. doi: 10.1016/j.biopha.2016.11.058. [PubMed: 27899255].
  • 48. Kang M, Sang Y, Gu H, Zheng L, Wang L, Liu C, et al. Long noncoding RNAs POLR2E rs3787016 C/T and HULC rs7763881 A/C polymorphisms are associated with decreased risk of esophageal cancer. Tumour Biol. 2015;36(8):6401-8. doi: 10.1007/s13277-015-3328-z. [PubMed: 25874495].
  • 49. Deng W, Wang J, Zhang J, Cai J, Bai Z, Zhang Z. TET2 regulates LncRNA-ANRIL expression and inhibits the growth of human gastric cancer cells. IUBMB Life. 2016;68(5):355-64. doi: 10.1002/iub.1490. [PubMed: 27027260].
  • 50. Zou ZW, Ma C, Medoro L, Chen L, Wang B, Gupta R, et al. LncRNA ANRIL is up-regulated in nasopharyngeal carcinoma and promotes the cancer progression via increasing proliferation, reprograming cell glucose metabolism and inducing side-population stem-like cancer cells. Oncotarget. 2016;7(38):61741-54. doi: 10.18632/oncotarget.11437. [PubMed: 27557514]. [PubMed Central: PMC5308687].
  • 51. Sayad A, Hajifathali A, Taheri M. Association of ANRIL gene polymorphisms with acute myeloid leukemia in an Iranian population. Int J Cancer Manag. 2017;10(10). doi: 10.5812/ijcm.11176.
  • 52. Yu G, Liu G, Yuan D, Dai J, Cui Y, Tang X. Long non-coding RNA ANRIL is associated with a poor prognosis of osteosarcoma and promotes tumorigenesis via PI3K/Akt pathway. J Bone Oncol. 2018;11:51-5. doi: 10.1016/j.jbo.2018.02.002. [PubMed: 29520337]. [PubMed Central: PMC5842283].
  • 53. Meseure D, Vacher S, Alsibai KD, Nicolas A, Chemlali W, Pasmant E. Expression of ANRIL "Polycomb Complexes" CDKN2A/B/ARF genes in breast tumours: Identification of a two-gene (EZH2/CBX7) signature with independent prognostic value. 29th European Congress of Pathology. RAI Amsterdam, The Netherlands. 2017.

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments